Encyclopedia of Psychopharmacology

Living Edition
| Editors: Ian P. Stolerman, Lawrence H. Price

Phosphodiesterase Inhibitors

  • Jos PrickaertsEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27772-6_403-2

Synonyms

PDE inhibitors

Definition

There are 11 families of phosphodiesterases (PDEs; PDE1–PDE11), which degrade the second messengers cAMP and/or cGMP. The activity of PDEs can be selectively inhibited with drugs. The most widely known PDE inhibitor is sildenafil, which is one of the three PDE5 inhibitors approved for the treatment of erectile dysfunction and also arterial pulmonary hypertension. In addition, two PDE3 inhibitors are approved for treating congestive heart failure or intermittent claudication, respectively. Recently, one PDE4 inhibitor has been approved for the treatment of chronic obstructive pulmonary disease. At the moment, PDE inhibitors are explored as possible therapeutic CNS drug targets for memory loss (PDE1, PDE2, PDE4, PDE5, PDE9), Alzheimer’s disease (PDE3, PDE4, PDE5, PDE7, PDE9), Parkinson’s disease (PDE1, PDE4, PDE7), Huntington’s disease (PDE1, PDE4, PDE5, PDE10), anxiety (PDE2, PDE5), depression (PDE4), schizophrenia (PDE3, PDE10), pain (PDE4, PDE5), or...

This is a preview of subscription content, log in to check access.

References

  1. Ambriz-Tututi M, Velazquez-Zamora DA, Urquiza-Marin H, Granados-Soto V (2005) Analysis of the mechanism underlying the peripheral antinociceptive action of sildenafil in the formalin test. Eur J Pharmacol 512:121–127PubMedCrossRefGoogle Scholar
  2. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488–520PubMedCrossRefGoogle Scholar
  3. Brink CB, Clapton JD, Eagar BE, Harvey BH (2008) Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies. J Neural Transm 115:117–125PubMedCrossRefGoogle Scholar
  4. Chapman TM, Goa KL (2003) Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 3:117–138PubMedCrossRefGoogle Scholar
  5. Cheng J, Grande JP (2007) Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Exp Biol Med (Maywood) 232:38–51Google Scholar
  6. Esposito K, Reierson GW, Rong Luo H, Sheng Wu G, Licinio J, Wong ML (2009) Phosphodiesterase genes and antidepressant treatment response: a review. Ann Med 41:177–185PubMedCrossRefGoogle Scholar
  7. García-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico AJ, Goicolea MA, Sallés J, Lanciego JL, Oyarzabal J, Franco R, Cuadrado-Tejedor M, García-Osta A (2013) Tadalafil crosses the blood–brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology 64:114–123PubMedCrossRefGoogle Scholar
  8. Gurney ME, Burgin AB, Magnusson OT, Stewart LJ (2011) Small molecule allosteric modulators of phosphodiesterase 4. Handb Exp Pharmacol 204:167–192PubMedCrossRefGoogle Scholar
  9. Keravis T, Lugnier C (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signaling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165:1288–1305PubMedCentralPubMedCrossRefGoogle Scholar
  10. Lahu G, Nassr N, Hünnemeyer A (2011) Pharmacokinetic evaluation of roflumilast. Expert Opin 7:1577–1591Google Scholar
  11. Lakics V, Karran EH, Boess FG (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:367–374PubMedCrossRefGoogle Scholar
  12. Liebenberg N, Harvey BH, Brand L, Wegener G, Brink CB (2012) Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats. Metab Brain Dis 27:337–340PubMedCrossRefGoogle Scholar
  13. Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660–670PubMedCrossRefGoogle Scholar
  14. Perez-Gonzalez R, Pascual C, Antequera D, Bolos M, Redondo M, Perez DI, Pérez-Grijalba V, Krzyzanowska A, Sarasa M, Gil C, Ferrer I, Martinez A, Carro E (2013) Phosphodiesterase 7 inhibitor reduced cognitive impairment and pathological hallmarks in a mouse model of Alzheimer’s disease. Neurobiol Aging 34:2133–2145PubMedCrossRefGoogle Scholar
  15. Puzzo D, Sapienza S, Arancio O, Palmeri A (2008) Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat 4:371–387PubMedCentralPubMedCrossRefGoogle Scholar
  16. Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 202:419–443CrossRefGoogle Scholar
  17. Sharma S, Kumar K, Deshmukh R, Sharma PL (2013) Phosphodiesterases: regulators of cyclic nucleotide signals and novel molecular target for movement disorders. Eur J Pharmacol 714:486–497PubMedCrossRefGoogle Scholar
  18. Shim YS, Pae CU, Kim SW, Kim HW, Kim JC, Koh JS (2011) Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: a pilot study. Int J Imp Res 23:109–114CrossRefGoogle Scholar
  19. Sierksma AS, Rutten K, Sydlik S, Rostamian S, Steinbusch HW, van den Hove DL, Prickaerts J (2013) Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Neuropharmacology 64:124–136PubMedCrossRefGoogle Scholar
  20. Szatmari SZ, Whitehouse PJ (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev(1), CD003119Google Scholar
  21. Xu Y, Zhang HT, O’Donnell JM (2011) Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. Handb Exp Pharmacol 204:447–485PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Psychiatry and NeuropsychologyUniversity of MaastrichtMaastrichtThe Netherlands